Nuvalent, Inc. (NUVL) research
Nuvalent, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $123.96
- As of
Nuvalent, Inc. (NUVL): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-15.
As of . Source: SEC EDGAR filings for NUVL. Method and limitations.
Share the NUVL intelligence card
See NUVL live in the terminal
Track NUVL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live NUVL terminal, freeActive signals for NUVL
- highCONSENSUS_BUY
7 tracked funds increased NUVL this 2026Q2, institutional consensus
- highCONSENSUS_BUY
5 tracked funds increased NUVL this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1879% to NUVL (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2138% to NUVL (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +216% to NUVL (2026Q2)
FREE, NO ACCOUNT
Every signal on NUVL, as it fires
You are seeing 5 of 43 signals recorded on NUVL since 2026-06-02.
The five above landed across 2 days. The other 38 were recorded on 3 other days. 36 of the 43 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NUVL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 670703107 · 2026Q2 | $49.9M | 0.02% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 670703107 · 2026Q2 | $37.1M | 0.46% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 670703107 · 2026Q2 | $34.7M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 670703107 · 2026Q2 | $25.8M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 670703107 · 2026Q2 | $5.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 670703107 · 2026Q2 | $5.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 670703107 · 2026Q2 | $817K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NUVL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NUVL against its peers
NUVL's return on equity of -34.1% ranks in the 32nd percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | NUVL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 389M | n/a | 15 |
| Operating margin | n/a | 5.6% | n/a | 13 |
| Net margin | n/a | -8.4% | n/a | 13 |
| Return on equity | -34.1% | -20.4% | 32 | 16 |
| P / E | n/a | 35.5x | n/a | 5 |
Peers (19): PTGX, KRYS, PRAX, ABVX, KYMR, APGE, CYTK, CRNX, IBRX, PCVX, TGTX, ARWR, SYRE, CAI, HALO, ALKS, BMRN, MDGL, IMVT. Left out: SBMFF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (NUVL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NUVL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NUVLand get the insider, 13F, options, and confluence read in one view.